Mediterranean diet, Metabolites, and Cardiovascular Disease

地中海饮食、代谢物和心血管疾病

• 批准号: 10385953
• 负责人: Frank B Hu
• 金额: $ 57.22万
• 依托单位: HARVARD SCHOOL OF PUBLIC HEALTH
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-07-15 至 2026-02-28
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10385953
• 关键词: Acute myocardial infarction; Adherence; Biological Markers; Body Fluids; Cardiovascular Diseases; Cardiovascular system; Cessation of life; Chickens; Chronic Disease; Complement; Consumption; Data; Data Analytics; Data Reporting; Diet; Dietary Assessment; Dietary Intervention; Dietary Practices; Dietary intake; Disease Outcome; Event; Fabaceae; Fasting; Fishes; Food; Food Patterns; Future; Goals; Grant; Heart failure; Individual; Intake; Intervention; Intervention Trial; Knowledge; Liquid substance; Measurement; Measures; Mediating; Mediterranean Diet; Metabolic; Myocardial Infarction; Nutrition Policy; Nutritional; Nutritional Study; Nuts; Olive oil preparation; Paper; Participant; Pathway interactions; Patient Self-Report; Pattern; Plasma; Prevention; Primary Prevention; Publishing; Randomized; Recommendation; Research; Resources; Risk; Role; Sampling; Spottings; Strategic Planning; Stroke; Techniques; Technology; Testing; United States National Institutes of Health; Urine; Work; base; cardiovascular disorder epidemiology; cardiovascular disorder prevention; cardiovascular disorder risk; cohort; design; dietary; dietary control; evidence base; fruits and vegetables; improved; metabolome; metabolomics; multidimensional data; multidisciplinary; novel; population based; post intervention; precision nutrition; predictive marker; red wine; research vision; response; tool; urinary

ABSTRACT Metabolomics technique holds promise for better understanding the role of diet in cardiovascular disease (CVD) epidemiology and prevention. In particular, a multi-fluid multi-metabolite approach combining urinary and plasma metabolomics will likely enhance the accuracy and precision of nutritional biomarkers, with strong potential to develop novel tools for dietary assessment in precision nutrition research. This competing renewal is aimed to examine the effects of the randomized Mediterranean diet (MedDiet) interventions on urinary metabolite levels and to assess dietary biomarkers' predictive ability for future CVD risk in the landmark PREDIMED trial. We will assess urinary metabolomics in relation to CVD through a case-cohort design, including a representative subcohort randomly sampled from all PREDIMED participants (10%, n=779), and incident CVD cases (including myocardial infarction (MI), stroke, heart failure, and cardiovascular deaths) through December 2017 (n=529). The proposed Specific Aims are: (1) To identify specific urinary metabolites and multi-metabolite signatures of the MedDiet pattern and its main food components; (2) To examine the effects of the randomized dietary interventions on changes in the urinary multi-metabolite signatures of the MedDiet pattern and its major food components from baseline to year 1 (post intervention); (3) To investigate whether baseline and 1-year changes in urinary multi-metabolite signatures of the MedDiet pattern and of individual foods are associated with subsequent risk of CVD; and (4) To develop a multi-fluid (urine and plasma) multi-metabolite signature that robustly predicts risk of CVD and assess whether 1-year changes in the signature mediate the effects of the dietary interventions on the composite CVD outcome. As a sub-aim, we will compare the predictive roles of plasma and urinary metabolites of the MedDiet pattern on CVD risk. This ongoing grant started in 2013 and was renewed in 2017. To date, 36 papers have been published or submitted (including 20 papers in the current grant cycle). The PREDIMED metabolomics data have been used as a resource for replicating metabolomics analyses of CVD outcomes in several US cohorts. This competing renewal application will extend our long-standing research on MedDiet and CVD to multi-fluid multi- metabolite profiling in a large randomized intervention trial. This project leverages numerous strengths of the PREDIMED trial, a multi-disciplinary and highly productive team, cutting-edge metabolomics technologies, and high-dimensional data analytics. The identified dietary biomarkers will enhance the quality and rigor of nutrition research and strengthen the evidence base for developing dietary recommendations and nutrition policies. The proposed work will facilitate the precision nutrition research agenda outlined in the 2020-2030 Strategic Plan for NIH Nutrition Research.

抽象的 代谢组学技术有望更好地了解饮食在心血管疾病（CVD）中的作用 流行病学和预防。特别是，多流体多富量代谢物方法结合了尿和 血浆代谢组学可能会提高营养生物标志物的准确性和精度 在精确营养研究中开发新颖的饮食评估工具的潜力。这种竞争的续约 旨在检查随机地中海饮食（Meddiet）干预措施的影响 代谢物水平并评估饮食生物标志物在地标中未来CVD风险的预测能力 predimed试验。我们将通过案例 - 霍特设计评估与CVD有关的尿代谢组学， 包括从所有Predimed参与者（10％，n = 779）和 事件CVD病例（包括心肌梗塞（MI），中风，心力衰竭和心血管死亡） 截至2017年12月（n = 529）。提出的特定目的是：（1）识别特定的尿尿代谢物 Meddiet模式及其主要食品成分的多代谢物特征； （2）检查 随机饮食干预措施对尿多代谢物特征变化的影响 从基线到第1年（干预后），Meddiet模式及其主要食品成分； （3）调查 基线和1年的尿尿多代谢物特征的变化以及 各个食物与随后的CVD风险有关； （4）开发多流体（尿液和 等离子体）多代谢物签名，可鲁棒预测CVD的风险，并评估1年的变化是否变化 该签名介导了饮食干预措施对复合CVD结果的影响。作为一个子，我们 将比较Meddiet模式在CVD风险中的血浆和尿代谢产物的预测作用。这 正在进行的赠款始于2013年，并于2017年续签。迄今为止，已经发表了36篇论文或 提交（包括当前赠款周期中的20篇论文）。 Predimed代谢组学数据已经 用作复制美国几个同类群体中CVD结果的代谢组学分析的资源。这 竞争的更新应用程序将使我们对Meddiet和CVD的长期研究扩展到多流体的多氟 在一项大型随机干预试验中代谢物分析。该项目利用了许多优势 Predimed试验，一支多学科和高产的团队，尖端的代谢组学技术，以及 高维数据分析。确定的饮食生物标志物将提高 营养研究并加强开发饮食建议和营养的证据基础 政策。拟议的工作将促进2020-2030概述的精确营养研究议程 NIH营养研究的战略计划。